Novo Nordisk’s stock is rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer.
24/7 Wall St.17d
HIMS Stock Craters - Is It a Buying Opportunity?
Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer healthcare platform said it couldn’t guarantee it would be able to continue ...
Generic drugmaker races to launch versions of blockbuster obesity drugs
Pharma group Hikma looks to take advantage as Novo Nordisk’s Wegovy and Ozempic start to go off patent next year ...
Becker's Hospital Review4d
Novo Nordisk drug yields 15.7% weight loss in phase 3 trial
Discover the latest experimental obesity drug from Novo Nordisk, achieving 15.7% weight loss after 68 weeks, which fell short of the company's expectations.
Fierce Pharma9d
Novo counters compounders with direct access channel for Wegovy, price cut for self-paying patients
Novo Nordisk is taking a page out of Eli Lilly’s playbook as the two GLP-1 drugmakers work to fend off compounding pharmacies ...
pharmaphorum15d
Novo Nordisk’s Victoza gets FDA okay for paediatric use
Victoza is Novo Nordisk’s once-daily injectable GLP-1 agonist and made around $3.6 billion in sales last year, making it the top-selling drug in the category.
Analysts Have Mixed Reviews on Hims & Hers Stock Amid Uncertainty Around Weight Loss Business
Telehealth company Hims & Hers Health (HIMS) witnessed a major dip in its stock recently despite reporting 95% revenue growth ...